Johnson Financial Group Inc. Boosts Holdings in Elevance Health, Inc. $ELV

Johnson Financial Group Inc. raised its position in shares of Elevance Health, Inc. (NYSE:ELV) by 285.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,087 shares of the company’s stock after purchasing an additional 8,948 shares during the quarter. Johnson Financial Group Inc.’s holdings in Elevance Health were worth $3,906,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC lifted its position in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares in the last quarter. Physician Wealth Advisors Inc. boosted its position in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares during the period. Rossby Financial LCC grew its position in Elevance Health by 110.0% in the third quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after acquiring an additional 44 shares in the last quarter. Activest Wealth Management lifted its holdings in shares of Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock worth $27,000 after buying an additional 34 shares during the last quarter. Finally, Motco boosted its holdings in shares of Elevance Health by 334.8% during the third quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after acquiring an additional 77 shares during the period. Institutional investors own 89.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ELV shares. Sanford C. Bernstein reduced their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Truist Financial decreased their target price on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Jefferies Financial Group cut their target price on Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Finally, JPMorgan Chase & Co. raised their price objective on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Trading Down 0.5%

ELV opened at $288.33 on Friday. The firm’s fifty day moving average price is $339.50 and its 200 day moving average price is $334.27. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The stock has a market capitalization of $63.64 billion, a PE ratio of 11.48, a P/E/G ratio of 1.60 and a beta of 0.51. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue was up 9.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is currently 27.39%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.